Monoclonal antibody · Immune activation, directed at ganglioside GD2 · developed by United Therap
Dinutuximab is a GD2-binding monoclonal antibody that binds the glycolipid GD2 on the surface of neuroblastoma cells and induces their lysis through antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. It is studied in neuroblastoma.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jul 6, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06450041 | Phase 2 | Neuroblastoma | Recruiting | UTHR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Neuroblastoma
Updated Nov 1, 2026. Something wrong or missing? Report it on the UTHR page.
See UTHR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
UTHR catalysts and pipeline →